AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Gartner, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Ionis Pharmaceuticals (IONS) filed a Form 4 disclosing routine board compensation for non-employee director Allene M. Diaz on 07/01/2025. She received:

  • 11,518 non-qualified stock options with a strike price of $39.94.
  • 5,220 restricted stock units (RSUs).

Under the company’s Non-Employee Director Compensation Policy, total 2025 equity value was capped at $450,000 (ASC 718 grant-date fair value), so the awards were adjusted downward to stay within that limit.

Both the options and RSUs vest 100 % on the earlier of (i) the first anniversary of the grant or (ii) the next annual shareholder meeting. No shares are currently vested or exercisable.

After the grant, Diaz beneficially owns 11,518 derivative option securities and 9,299 RSUs, all held directly. No open-market purchases or sales occurred, and no cash changed hands; the filing reflects standard equity grants intended to align director incentives with shareholder interests.

Ionis Pharmaceuticals (IONS) ha presentato un Modulo 4 per comunicare la consueta retribuzione del consiglio di amministrazione per la direttrice non dipendente Allene M. Diaz il 01/07/2025. Ha ricevuto:

  • 11.518 opzioni su azioni non qualificate con prezzo di esercizio di 39,94 $.
  • 5.220 unità azionarie vincolate (RSU).

Secondo la Politica di Compensazione per Direttori Non Dipendenti della società, il valore totale delle azioni per il 2025 è stato limitato a 450.000 $ (valore equo alla data di concessione secondo ASC 718), pertanto le assegnazioni sono state ridotte per rispettare questo limite.

Sia le opzioni che le RSU maturano al 100% al verificarsi dell’evento che avviene per primo tra (i) il primo anniversario della concessione o (ii) la successiva assemblea annuale degli azionisti. Attualmente nessuna azione è maturata o esercitabile.

Dopo la concessione, Diaz detiene beneficiariamente 11.518 titoli derivati da opzioni e 9.299 RSU, tutti detenuti direttamente. Non si sono verificate compravendite sul mercato aperto e non sono stati scambiati contanti; la comunicazione riflette assegnazioni azionarie standard volte ad allineare gli incentivi del direttore con gli interessi degli azionisti.

Ionis Pharmaceuticals (IONS) presentó un Formulario 4 revelando la compensación habitual del consejo para la directora no empleada Allene M. Diaz el 01/07/2025. Ella recibió:

  • 11,518 opciones sobre acciones no calificadas con un precio de ejercicio de $39.94.
  • 5,220 unidades de acciones restringidas (RSUs).

Bajo la Política de Compensación para Directores No Empleados de la empresa, el valor total de capital para 2025 se limitó a $450,000 (valor razonable en la fecha de concesión según ASC 718), por lo que las adjudicaciones se ajustaron a la baja para mantenerse dentro de ese límite.

Tanto las opciones como las RSUs se consolidan al 100% en la primera de las siguientes fechas: (i) el primer aniversario de la concesión o (ii) la próxima junta anual de accionistas. Actualmente no hay acciones consolidadas ni ejercitables.

Después de la concesión, Diaz posee beneficiosamente 11,518 valores derivados de opciones y 9,299 RSUs, todos en propiedad directa. No hubo compras ni ventas en el mercado abierto, ni intercambio de efectivo; la presentación refleja concesiones estándar de capital destinadas a alinear los incentivos del director con los intereses de los accionistas.

Ionis Pharmaceuticals(IONS)ëŠ� 2025ë…� 7ì›� 1ì� 비임ì›� ì´ì‚¬ Allene M. Diazì—� 대í•� 정기 ì´ì‚¬íš� ë³´ìƒì� 공개하는 Form 4ë¥� 제출했습니다. 그녀ëŠ� 다ìŒì� 받았습니ë‹�:

  • 11,518 비ìžê²� 스톡옵션, 행사가ê²� $39.94.
  • 5,220 제한주ì‹ë‹¨ìœ„(¸é³§±«).

회사ì� 비임ì›� ì´ì‚¬ ë³´ìƒ ì •ì±…ì—� ë”°ë¼ 2025ë…� ì´� ì£¼ì‹ ê°€ì¹˜ëŠ” $450,000 (ASC 718 ë¶€ì—¬ì¼ ê³µì •ê°€ì¹�)ë¡� ìƒí•œì� 설정ë˜ì–´ 있어, 수여 ì£¼ì‹ ìˆ˜ëŠ” ì� í•œë„ ë‚´ë¡œ ì¡°ì •ë˜ì—ˆìŠµë‹ˆë‹�.

옵션ê³� RSU ëª¨ë‘ 100% 완전íž� ì·¨ë“ë˜ë©°, ì´ëŠ” (i) ë¶€ì—¬ì¼ 1주년 ë˜ëŠ” (ii) ë‹¤ìŒ ì—°ë¡€ 주주ì´íšŒ ì¤� 빠른 ë‚ ì§œì—� 해당합니ë‹�. 현재 ì·¨ë“ë˜ê±°ë‚� 행사 가능한 주ì‹ì€ 없습니다.

수여 í›� DiazëŠ� ì§ì ‘ 보유í•� 11,518 íŒŒìƒ ì˜µì…˜ ì¦ê¶Œê³� 9,299 RSUë¥� 실질ì ìœ¼ë¡� 소유하고 있습니다. 공개 시장ì—서ì� 매매ëŠ� 없었으며 현금 거래ë� 없었ê³�, ì´ë²ˆ ì‹ ê³ ëŠ� ì´ì‚¬ì� ì¸ì„¼í‹°ë¸Œë¥� 주주 ì´ìµê³� ì¼ì¹˜ì‹œí‚¤ê¸� 위한 표준 ì£¼ì‹ ìˆ˜ì—¬ë¥� ë°˜ì˜í•©ë‹ˆë‹�.

Ionis Pharmaceuticals (IONS) a déposé un formulaire 4 révélant la rémunération habituelle du conseil d'administration pour la directrice non salariée Allene M. Diaz le 01/07/2025. Elle a reçu :

  • 11 518 options d'achat d'actions non qualifiées avec un prix d'exercice de 39,94 $.
  • 5 220 unités d'actions restreintes (RSU).

Selon la politique de rémunération des administrateurs non salariés de la société, la valeur totale des actions pour 2025 était plafonnée à 450 000 $ (juste valeur à la date d'attribution selon ASC 718), les attributions ont donc été ajustées à la baisse pour respecter cette limite.

Les options et les RSU acquièrent 100 % à la première des dates suivantes : (i) le premier anniversaire de l'attribution ou (ii) la prochaine assemblée générale annuelle. Aucune action n'est actuellement acquise ni exerçable.

Après l'attribution, Diaz détient de manière bénéficiaire 11 518 titres dérivés d'options et 9 299 RSU, tous détenus directement. Aucune transaction sur le marché ouvert n'a eu lieu et aucun échange d'argent n'a eu lieu ; le dépôt reflète des attributions d'actions standard visant à aligner les incitations de l'administrateur avec les intérêts des actionnaires.

Ionis Pharmaceuticals (IONS) hat am 01.07.2025 ein Formular 4 eingereicht, in dem die routinemäßige Vergütung für die nicht geschäftsführende Direktorin Allene M. Diaz offengelegt wird. Sie erhielt:

  • 11.518 nicht qualifizierte Aktienoptionen mit einem Ausübungspreis von 39,94 $.
  • 5.220 Restricted Stock Units (RSUs).

Gemäß der Vergütungspolitik für nicht geschäftsführende Direktoren des Unternehmens war der Gesamtwert der Aktienvergütung für 2025 auf 450.000 $ (Fair Value zum Gewährungszeitpunkt gemäß ASC 718) begrenzt, weshalb die Zuteilungen entsprechend angepasst wurden.

Sowohl die Optionen als auch die RSUs vesten zu 100 % zum früheren Zeitpunkt von (i) dem ersten Jahrestag der Gewährung oder (ii) der nächsten jährlichen Hauptversammlung. Aktuell sind keine Aktien vestet oder ausübbar.

Nach der Zuteilung besitzt Diaz wirtschaftlich 11.518 derivative Optionswerte und 9.299 RSUs, alle direkt gehalten. Es gab keine Käufe oder Verkäufe am offenen Markt, und es floss kein Bargeld; die Meldung spiegelt Standardaktienzuteilungen wider, die darauf abzielen, die Anreize des Direktors mit den Interessen der Aktionäre in Einklang zu bringen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director equity grant; neutral for valuation, confirms ongoing incentive alignment without cash outflow.

The filing shows typical non-employee director compensation: options equal to 11,518 shares at $39.94 and 5,220 RSUs. Because these are grants—not open-market buys—they do not signal bullish insider sentiment but do maintain alignment with shareholders. The capped $450k fair-value conforms with governance best practices and limits dilution risk. Overall, the event has negligible EPS or cash-flow impact, so I view it as neutral for investors.

TL;DR: Grant adheres to policy cap; good governance but financially immaterial.

The company continues to enforce a hard ceiling on annual director equity compensation, strengthening governance transparency. One-year cliff vesting is standard and provides retention without excessive entrenchment. No red flags on dilution (�0.007 % of basic shares outstanding, assuming ~150 M shares). Because this is scheduled remuneration, market impact remains minimal.

Ionis Pharmaceuticals (IONS) ha presentato un Modulo 4 per comunicare la consueta retribuzione del consiglio di amministrazione per la direttrice non dipendente Allene M. Diaz il 01/07/2025. Ha ricevuto:

  • 11.518 opzioni su azioni non qualificate con prezzo di esercizio di 39,94 $.
  • 5.220 unità azionarie vincolate (RSU).

Secondo la Politica di Compensazione per Direttori Non Dipendenti della società, il valore totale delle azioni per il 2025 è stato limitato a 450.000 $ (valore equo alla data di concessione secondo ASC 718), pertanto le assegnazioni sono state ridotte per rispettare questo limite.

Sia le opzioni che le RSU maturano al 100% al verificarsi dell’evento che avviene per primo tra (i) il primo anniversario della concessione o (ii) la successiva assemblea annuale degli azionisti. Attualmente nessuna azione è maturata o esercitabile.

Dopo la concessione, Diaz detiene beneficiariamente 11.518 titoli derivati da opzioni e 9.299 RSU, tutti detenuti direttamente. Non si sono verificate compravendite sul mercato aperto e non sono stati scambiati contanti; la comunicazione riflette assegnazioni azionarie standard volte ad allineare gli incentivi del direttore con gli interessi degli azionisti.

Ionis Pharmaceuticals (IONS) presentó un Formulario 4 revelando la compensación habitual del consejo para la directora no empleada Allene M. Diaz el 01/07/2025. Ella recibió:

  • 11,518 opciones sobre acciones no calificadas con un precio de ejercicio de $39.94.
  • 5,220 unidades de acciones restringidas (RSUs).

Bajo la Política de Compensación para Directores No Empleados de la empresa, el valor total de capital para 2025 se limitó a $450,000 (valor razonable en la fecha de concesión según ASC 718), por lo que las adjudicaciones se ajustaron a la baja para mantenerse dentro de ese límite.

Tanto las opciones como las RSUs se consolidan al 100% en la primera de las siguientes fechas: (i) el primer aniversario de la concesión o (ii) la próxima junta anual de accionistas. Actualmente no hay acciones consolidadas ni ejercitables.

Después de la concesión, Diaz posee beneficiosamente 11,518 valores derivados de opciones y 9,299 RSUs, todos en propiedad directa. No hubo compras ni ventas en el mercado abierto, ni intercambio de efectivo; la presentación refleja concesiones estándar de capital destinadas a alinear los incentivos del director con los intereses de los accionistas.

Ionis Pharmaceuticals(IONS)ëŠ� 2025ë…� 7ì›� 1ì� 비임ì›� ì´ì‚¬ Allene M. Diazì—� 대í•� 정기 ì´ì‚¬íš� ë³´ìƒì� 공개하는 Form 4ë¥� 제출했습니다. 그녀ëŠ� 다ìŒì� 받았습니ë‹�:

  • 11,518 비ìžê²� 스톡옵션, 행사가ê²� $39.94.
  • 5,220 제한주ì‹ë‹¨ìœ„(¸é³§±«).

회사ì� 비임ì›� ì´ì‚¬ ë³´ìƒ ì •ì±…ì—� ë”°ë¼ 2025ë…� ì´� ì£¼ì‹ ê°€ì¹˜ëŠ” $450,000 (ASC 718 ë¶€ì—¬ì¼ ê³µì •ê°€ì¹�)ë¡� ìƒí•œì� 설정ë˜ì–´ 있어, 수여 ì£¼ì‹ ìˆ˜ëŠ” ì� í•œë„ ë‚´ë¡œ ì¡°ì •ë˜ì—ˆìŠµë‹ˆë‹�.

옵션ê³� RSU ëª¨ë‘ 100% 완전íž� ì·¨ë“ë˜ë©°, ì´ëŠ” (i) ë¶€ì—¬ì¼ 1주년 ë˜ëŠ” (ii) ë‹¤ìŒ ì—°ë¡€ 주주ì´íšŒ ì¤� 빠른 ë‚ ì§œì—� 해당합니ë‹�. 현재 ì·¨ë“ë˜ê±°ë‚� 행사 가능한 주ì‹ì€ 없습니다.

수여 í›� DiazëŠ� ì§ì ‘ 보유í•� 11,518 íŒŒìƒ ì˜µì…˜ ì¦ê¶Œê³� 9,299 RSUë¥� 실질ì ìœ¼ë¡� 소유하고 있습니다. 공개 시장ì—서ì� 매매ëŠ� 없었으며 현금 거래ë� 없었ê³�, ì´ë²ˆ ì‹ ê³ ëŠ� ì´ì‚¬ì� ì¸ì„¼í‹°ë¸Œë¥� 주주 ì´ìµê³� ì¼ì¹˜ì‹œí‚¤ê¸� 위한 표준 ì£¼ì‹ ìˆ˜ì—¬ë¥� ë°˜ì˜í•©ë‹ˆë‹�.

Ionis Pharmaceuticals (IONS) a déposé un formulaire 4 révélant la rémunération habituelle du conseil d'administration pour la directrice non salariée Allene M. Diaz le 01/07/2025. Elle a reçu :

  • 11 518 options d'achat d'actions non qualifiées avec un prix d'exercice de 39,94 $.
  • 5 220 unités d'actions restreintes (RSU).

Selon la politique de rémunération des administrateurs non salariés de la société, la valeur totale des actions pour 2025 était plafonnée à 450 000 $ (juste valeur à la date d'attribution selon ASC 718), les attributions ont donc été ajustées à la baisse pour respecter cette limite.

Les options et les RSU acquièrent 100 % à la première des dates suivantes : (i) le premier anniversaire de l'attribution ou (ii) la prochaine assemblée générale annuelle. Aucune action n'est actuellement acquise ni exerçable.

Après l'attribution, Diaz détient de manière bénéficiaire 11 518 titres dérivés d'options et 9 299 RSU, tous détenus directement. Aucune transaction sur le marché ouvert n'a eu lieu et aucun échange d'argent n'a eu lieu ; le dépôt reflète des attributions d'actions standard visant à aligner les incitations de l'administrateur avec les intérêts des actionnaires.

Ionis Pharmaceuticals (IONS) hat am 01.07.2025 ein Formular 4 eingereicht, in dem die routinemäßige Vergütung für die nicht geschäftsführende Direktorin Allene M. Diaz offengelegt wird. Sie erhielt:

  • 11.518 nicht qualifizierte Aktienoptionen mit einem Ausübungspreis von 39,94 $.
  • 5.220 Restricted Stock Units (RSUs).

Gemäß der Vergütungspolitik für nicht geschäftsführende Direktoren des Unternehmens war der Gesamtwert der Aktienvergütung für 2025 auf 450.000 $ (Fair Value zum Gewährungszeitpunkt gemäß ASC 718) begrenzt, weshalb die Zuteilungen entsprechend angepasst wurden.

Sowohl die Optionen als auch die RSUs vesten zu 100 % zum früheren Zeitpunkt von (i) dem ersten Jahrestag der Gewährung oder (ii) der nächsten jährlichen Hauptversammlung. Aktuell sind keine Aktien vestet oder ausübbar.

Nach der Zuteilung besitzt Diaz wirtschaftlich 11.518 derivative Optionswerte und 9.299 RSUs, alle direkt gehalten. Es gab keine Käufe oder Verkäufe am offenen Markt, und es floss kein Bargeld; die Meldung spiegelt Standardaktienzuteilungen wider, die darauf abzielen, die Anreize des Direktors mit den Interessen der Aktionäre in Einklang zu bringen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bisson Peter

(Last) (First) (Middle)
56 TOP GALLANT ROAD

(Street)
STAMFORD CT 06904

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GARTNER INC [ IT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Equivalent (CSE) $0 07/01/2025 A 65 (1) (1) Common Stock 65 $406.7 3,471 D
Explanation of Responses:
1. These are Common Stock Equivalents ("CSEs") received as compensation for service as an outside director of Gartner, Inc. They were granted under the Gartner, Inc. Long-Term Incentive Plan ("LTIP"). The CSEs convert into Gartner common stock on the date the outside director's continuous status as a director terminates, or as otherwise provided in the LTIP.
/s/ Jenna Gallagher for Peter Bisson 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Gartner Inc

NYSE:IT

IT Rankings

IT Latest News

IT Latest SEC Filings

IT Stock Data

31.30B
74.64M
2.92%
95.51%
2.12%
Information Technology Services
Services-management Services
United States
STAMFORD